GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » argenx SE (MEX:ARGX) » Definitions » 3-Year FCF Growth Rate

argenx SE (MEX:ARGX) 3-Year FCF Growth Rate : 44.00% (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is argenx SE 3-Year FCF Growth Rate?

argenx SE's Free Cash Flow per Share for the three months ended in Dec. 2024 was MXN0.00.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 44.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of argenx SE was 68.00% per year. The lowest was -97.40% per year. And the median was -22.00% per year.


Competitive Comparison of argenx SE's 3-Year FCF Growth Rate

For the Biotechnology subindustry, argenx SE's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


argenx SE's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, argenx SE's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where argenx SE's 3-Year FCF Growth Rate falls into.


;
;

argenx SE 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


argenx SE  (MEX:ARGX) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


argenx SE 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of argenx SE's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


argenx SE Business Description

Address
Laarderhoogtweg 25, Amsterdam, NH, NLD, 1101EB
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.